Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account> 90% of
thyroid cancer (TC)[papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%] …

The incidence of thyroid cancer continues to increase and this neoplasia remains the most
common endocrine malignancy. No effective systemic treatment currently exists for iodine …

Opinion statement With a growing understanding of the biologic drivers of different thyroid
cancers, there is an ongoing revolution in the treatment of aggressive and advanced …

Thyroid cancer (TC) is the most common endocrine malignancy with steadily increasing
incidence over the past few decades. Although standard strategies for the management of …

Therapeutic options for advanced, unresectable radioiodine-resistant thyroid cancers have
historically been limited. Recent progress in understanding the pathogenesis of the various …

Although generally the prognosis of differentiated thyroid carcinoma (DTC) is good,
approximately 5% of people are likely to develop metastases which fail to respond to …

Simple Summary This article reviews current treatment practices for thyroid cancer with a
focus on novel targeted molecular therapy. Rapidly expanding knowledge of the molecular …

Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
incidence in the past 20 years. Surgery is the primary strategy of therapy for patients with …

Landmark studies published in 2010 have shed new light on the biology of thyroid cancer.
From cooperation between various genetic lesions during thyroid carcinogenesis to …

Introduction: While the vast majority of patients with thyroid cancer have an excellent
prognosis, those with more aggressive courses experience significant morbidity and …